Company
OncoSil Medical Ltd
ASX:OSL
OncoSil Medical is a global medical device company focused on Interventional Oncology. The company's mission is to improve the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in addition to chemotherapy.
61 stories
NWR Communications virtual health and biotech conference starts today
The two-day Virtual Small Cap Conference is on today and Monday featuring health, biotech and medtech companies.
OncoSil Medical attracts $16.7 million for breakthrough pancreatic cancer radiation treatment
OncoSil is a first in class medical device for the treatment of unresectable locally advanced pancreatic cancer.
OncoSil Medical seen as undervalued by broker following success with pancreatic cancer treatment trials
The global target market for pancreatic and liver cancer is estimated to be about US$3.5 billion.
OncoSil Medical reveals positive data from pancreatic cancer clinical study
100% disease control rate achieved by the company's device at week 8.
OncoSil Medical gets ready to present pancreatic cancer clinical study data
More concentrated and localised beta radiation compared to external beam radiation.
OncoSil Medical continues to advance its pancreatic cancer study
10 subjects in the study group have now been successfully implanted with the device.
OncoSil Medical achieves steady progress in pancreatic cancer study
A CE Mark application to commercially sell OncoSil™ in Europe is under review.
OncoSil Medical wins key approval
OncoSil is focused on treatments for pancreatic and liver cancer.
Oncosil Medical attracts broker attention
Oncosil has enrolled the first patient in the OncoPac-1 trial.
OncoSil Medical crosses a milestone in global pancreatic cancer study
Recruited the first subject for a global study of OncoSil™ device.
OncoSil Medical outlines timeline for CE Mark
OncoSil is well positioned to collect the supplemental data quickly.
OncoSil Medical Ltd updates on Pancreatic Cancer Clinical Study
Daniel Kenny, chief executive officer, commented: "I am are delighted with the participation of these four prestigious centres in our global clinical program."
OncoSil Medical Ltd: Broker boosts price target
OncoSil Medical Ltd has been receiving a lot of broker attention recently.
OncoSil Medical Ltd's well-funded and delivering milestones
OncoSil Medical Ltd (ASX:OSL) ended the September quarter with $13.8 million in cash, and during the period delivered milestones.
OncoSil Medical Ltd receives a Buy recommendation
OncoSil has received a Buy rating and $0.42 per share price target from Wilsons Research.
OncoSil Medical Ltd swells cash position after tax refund
OncoSil is a clinical-stage medical device company seeking to provide a new medical radiation treatment for cancer subjects.
OncoSil Medical Ltd completes key step towards commercial sales
The manufacturing, supply chain validation and delivery to clinical and commercial centres of the OncoSil product is a key step to commercial sales and the treatment of patients in the OncoPac-1 study.
OncoSil Medical Ltd shines under broker spotlight
OncoSil has been receiving some strong broker attention recently, as the company moves closer to commercial revenue.
Oncosil Medical Ltd: Commercial Revenues Closer
Bell Potter noted: "The awarding of the IDE is a major step forward for this first in class therapy, consequently the valuation is raised by 10% to $0.33."
OncoSil Medical Ltd: IDE Approval from the U.S. Food and Drug Administration
Daniel Kenny, CEO, commented: “We are delighted to receive FDA approval for the IDE which is a significant milestone in our regulatory pathway and a validation of our product and supporting processes to commence this important clinica
OncoSil Medical Ltd confident of a successful outcome with the FDA
OncoSil has continued to make progress with its two key regulatory filings during the June quarter 2016, which remain the primary focus and value enablers for the OncoSil™ technology.
OncoSil Medical Ltd remains confident on CE Mark and IDE submissions
Daniel Kenny, CEO, commented: "We are delighted with the progress we have been making to prosecute and progress both our CE mark and IDE submissions."
OncoSil Medical Ltd: Thoughts on OncoSil's regulatory situation
WilsonHTM noted: "If the FDA allows Oncosil’s IDE study in the coming months, then that should correspond to more regular positive new flow over the balance of 2016."
OncoSil Medical Ltd confident CE Mark will be granted in near-term
Daniel Kenny, CEO, said: "Our key focus in the shorter term is to achieve the CE Mark and enable commercial launch and first sales. We remain optimistic about a favourable decision shortly on the CE Mark."
OncoSil Medical Ltd: Van Leeuwenhoek applies $0.80 per share valuation
Van Leeuwenhoek wrote: "Based on our NPV valuation, we believe that OncoSil Medical is substantially undervalued at the current share price of AUD 0.16."
OncoSil Medical updates on CE Mark, Regal Funds joins share register
OncoSil added that it remains confident in its submission for CE Mark being granted, thereby enabling commercial sales to commence in the European Union and application for TGA approval in Australia.
OncoSil Medical: Speculative Buy and $0.50 target from broker
WilsonHTM said: "We maintain a Speculative Buy. No change to target price of 50 cps which was pre-emptively diluted for anticipated capital raising event(s) in FY16-17."
OncoSil Medical bags $10M to commercialise cancer treatment
OncoSil Medical has raised A$10 million for the commercialisation of its namesake cancer treatment as a number of regulatory approvals come into focus.
OncoSil Medical share price target upgraded by broker
WilsonHTM has compiled a research report on OncoSil Medical, maintaining a speculative buy rating and upgrading its target price.
ASX closes higher with a strong show by this medical supplier
The Australian All Ordinaries gathered pace today as this value-adding medical supply company helped health care stocks contribute to a widespread turnaround on the local market.
ASX edges down as this medical play marks gains
The Australian All Ordinaries ticked another 0.4% lower today, but a lacklustre session for healthcare stocks didn’t hold back this lifesciences company.
OncoSil Medical files Investigational Device Exemption submission with FDA
Daniel Kenny, CEO, OncoSil, commented: “I am delighted to report that we have filed our Investigational Device Exemption submission with the US FDA. This represents a key milestone in the development timeline for OncoSil™ in the
OncoSil Medical completes Fast Track Face-to-Face for CE Mark
The CE Mark is the mandatory regulatory designation required to commercially market and sell the OncoSil™ medical device in the European Union. OncoSil now awaits the final outcome of the review as the Notified Body continues its asse
OncoSil Medical valued at A$0.35 price target: broker
Wilson HTM has initiated coverage on OncoSil Medical with a Speculative Buy rating and a price target of A$0.35. The target is more than double the company's last trading price of $0.15.
OncoSil Medical receives hefty valuation from research firm
OncoSil has received a valuation of A$175-210 million from a European life sciences research group.
OncoSil Medical's device scheduled for CE Mark Fast Track review
A CE Mark is the mandatory regulatory designation required to commercially market and sell OncoSil™ in the European Union. This would be a company-making milestone.
OncoSil Medical Melbourne/Sydney Investor Luncheon Presentation
OncoSil Medical Melbourne/Sydney Investor Luncheon Presentation